S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

$0.37
0.00 (0.00%)
(As of 02/29/2024 ET)
Today's Range
$0.34
$0.38
50-Day Range
$0.20
$0.39
52-Week Range
$0.13
$3.46
Volume
1.52 million shs
Average Volume
872,642 shs
Market Capitalization
$17.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Brainstorm Cell Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
2,624.8% Upside
$10.00 Price Target
Short Interest
Healthy
2.51% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.66
Upright™ Environmental Score
News Sentiment
0.35mentions of Brainstorm Cell Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.98 out of 5 stars

Medical Sector

195th out of 959 stocks

Biological Products, Except Diagnostic Industry

25th out of 152 stocks


BCLI stock logo

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

BCLI Stock Price History

BCLI Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
BCLI Mar 2024 1.500 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Brainstorm Cell Therapeutics Inc.
Brainstorm Cell Therapeutics Inc (BCLI)
Brainstorm Cell Therapeutics Inc. (BCLI)
BCLI Brainstorm Cell Therapeutics Inc.
BrainStorm Issues 2023 Letter to Shareholders
See More Headlines
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
2/29/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BCLI
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+2,624.8%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.08) per share

Miscellaneous

Free Float
46,312,000
Market Cap
$17.98 million
Optionable
Optionable
Beta
0.22
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Mr. Chaim Lebovits (Age 53)
    President & CEO
    Comp: $990.42k
  • Dr. Stacy R. Lindborg Ph.D. (Age 54)
    Co-Chief Executive Officer
    Comp: $708.39k
  • Dr. Irit Arbel DSc (Age 64)
    Ph.D., Co-Founder & Independent Vice Chair of the Board
  • Mr. Uri Yablonka (Age 47)
    Executive VP, Chief Business Officer, Secretary & Director
  • Ms. Alla Patlis CPA (Age 37)
    M.B.A., Controller & Interim CFO
    Comp: $80k
  • Dr. Yael Gothelf
    Vice President of Scientific & Regulatory Affairs
  • Ms. Antal Pearl-Lendner
    VP & Chief Legal Counsel
  • Dr. Daniel Offen Ph.D.
    Chief Scientific Advisor
  • Ms. Mary Kay Turner
    Senior Vice President of Patient Advocacy & Government Affairs
  • Mr. William K. White
    Senior VP & Head of Market Access and Pricing














BCLI Stock Analysis - Frequently Asked Questions

Should I buy or sell Brainstorm Cell Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Brainstorm Cell Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BCLI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BCLI, but not buy additional shares or sell existing shares.
View BCLI analyst ratings
or view top-rated stocks.

What is Brainstorm Cell Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month target prices for Brainstorm Cell Therapeutics' shares. Their BCLI share price targets range from $10.00 to $10.00. On average, they anticipate the company's share price to reach $10.00 in the next year. This suggests a possible upside of 2,624.8% from the stock's current price.
View analysts price targets for BCLI
or view top-rated stocks among Wall Street analysts.

How have BCLI shares performed in 2024?

Brainstorm Cell Therapeutics' stock was trading at $0.2730 at the beginning of the year. Since then, BCLI stock has increased by 34.4% and is now trading at $0.3670.
View the best growth stocks for 2024 here
.

Are investors shorting Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 1,230,000 shares, a decrease of 39.4% from the January 31st total of 2,030,000 shares. Based on an average daily volume of 2,380,000 shares, the days-to-cover ratio is currently 0.5 days.
View Brainstorm Cell Therapeutics' Short Interest
.

When is Brainstorm Cell Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our BCLI earnings forecast
.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) announced its quarterly earnings data on Tuesday, November, 14th. The biotechnology company reported ($0.14) EPS for the quarter, hitting analysts' consensus estimates of ($0.14). During the same period last year, the company posted ($0.19) EPS.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Brainstorm Cell Therapeutics investors own include Organovo (ONVO), Gene Biotherapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Mellanox Technologies (MLNX), Caladrius Biosciences (CLBS), Abeona Therapeutics (ABEO) and Adaptimmune Therapeutics (ADAP).

Who are Brainstorm Cell Therapeutics' major shareholders?

Brainstorm Cell Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ADAR1 Capital Management LLC (0.00%), Barclays PLC (0.00%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCLI) was last updated on 3/1/2024 by MarketBeat.com Staff